Literature DB >> 9885224

Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr virus-transformed lymphoid cells.

H Dürkop1, H D Foss, G Demel, H Klotzbach, C Hahn, H Stein.   

Abstract

The tumor necrosis factor (TNF) receptor-associated factor 1 (TRAF1) is a member of the recently defined TRAF family. It takes part in the signal transduction of the TNF receptor 2 (TNFR2), the lymphotoxin-beta receptor (LT-betaR), CD40, CD30, and LMP1; is induced by LMP1 in vitro; and protects lymphoid cells from apoptosis. To identify the cells in which TRAF1 is active in vivo, we studied TRAF1 transcripts in normal lymphoid tissue, in Epstein-Barr virus (EBV)-induced lymphoproliferations, and in malignant lymphomas with special reference to those that overexpress the cytokine receptor CD30 and CD40 of the TNF receptor family at the single-cell level using a radioactive in situ hybridization. In normal lymphoid tissue, TRAF1 message proved to be absent from all resting B and T cells as well as from macrophages and accessory cells (follicular dendritic cells and interdigitating cells) and present in few perifollicular and intrafollicular lymphoid blasts. In contrast, there was a high and consistent TRAF1 overexpression in EBV-induced lymphoproliferations and Hodgkin's disease. Nearly all non-Hodgkin's lymphoma show low or no TRAF1 expression. Only some cases of diffuse large B-cell lymphoma showed a moderate to high TRAF1 signal. Several of the latter cases were EBV+. These data confirm that TRAF1 is an inducible molecule and indicates its deregulation in the mentioned disorders with the potential of a blockage of the apoptotic pathway.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9885224

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  Hodgkin's disease and the Epstein-Barr virus.

Authors:  K J Flavell; P G Murray
Journal:  Mol Pathol       Date:  2000-10

Review 2.  Prognostic factors in pediatric Hodgkin disease.

Authors:  Cindy L Schwartz
Journal:  Curr Oncol Rep       Date:  2003-11       Impact factor: 5.075

3.  TRAF1 is a critical regulator of JNK signaling by the TRAF-binding domain of the Epstein-Barr virus-encoded latent infection membrane protein 1 but not CD40.

Authors:  Aristides G Eliopoulos; Elyse R Waites; Sarah M S Blake; Clare Davies; Paul Murray; Lawrence S Young
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma.

Authors:  Jitakshi De; Robert E Brown
Journal:  Int J Clin Exp Med       Date:  2010-01-30

5.  NF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis.

Authors:  Baochun Zhang; Zhe Wang; Tai Li; Erdyni N Tsitsikov; Han-Fei Ding
Journal:  Blood       Date:  2007-04-03       Impact factor: 22.113

6.  Translation of TRAF1 is regulated by IRES-dependent mechanism and stimulated by vincristine.

Authors:  Lin Yang; Lubing Gu; Zhuoya Li; Muxiang Zhou
Journal:  Nucleic Acids Res       Date:  2010-04-22       Impact factor: 16.971

7.  RIP2, a checkpoint in myogenic differentiation.

Authors:  Barbara Munz; Eberhard Hildt; Matthew L Springer; Helen M Blau
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

8.  Epstein-Barr virus encoded latent membrane protein 1 (LMP1) and TNF receptor associated factors (TRAF): colocalisation of LMP1 and TRAF1 in primary EBV infection and in EBV associated Hodgkin lymphoma.

Authors:  G Siegler; E Kremmer; R Gonnella; G Niedobitek
Journal:  Mol Pathol       Date:  2003-06

Review 9.  Hodgkin's lymphoma and CD30 signal transduction.

Authors:  Ryouichi Horie; Masaaki Higashihara; Toshiki Watanabe
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

Review 10.  Epstein-Barr virus and Hodgkin's disease.

Authors:  L M Weiss
Journal:  Curr Oncol Rep       Date:  2000-03       Impact factor: 5.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.